Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Significant Growth in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 16,400 shares, a growth of 30.2% from the February 28th total of 12,600 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily volume of 77,600 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Comprehensive Money Management Services LLC bought a new stake in Global X Genomics & Biotechnology ETF in the 4th quarter worth about $178,000. Armis Advisers LLC bought a new position in shares of Global X Genomics & Biotechnology ETF in the fourth quarter valued at approximately $432,000. Two Sigma Investments LP increased its position in shares of Global X Genomics & Biotechnology ETF by 74.5% during the fourth quarter. Two Sigma Investments LP now owns 85,500 shares of the company’s stock valued at $830,000 after acquiring an additional 36,500 shares during the last quarter. Strive Asset Management LLC bought a new stake in Global X Genomics & Biotechnology ETF during the fourth quarter worth $409,000. Finally, Citadel Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF during the fourth quarter worth $148,000. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Trading Down 4.8 %

Shares of NASDAQ:GNOM traded down $0.40 during mid-day trading on Monday, hitting $7.95. 513,392 shares of the company traded hands, compared to its average volume of 61,877. The stock has a market cap of $55.41 million, a P/E ratio of -3.40 and a beta of 1.03. The stock has a 50-day moving average price of $9.44 and a two-hundred day moving average price of $10.14. Global X Genomics & Biotechnology ETF has a 12-month low of $7.85 and a 12-month high of $11.88.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.